Bis(4-cyanophenyl)methanol
CAS: 134521-16-7
Ref. 3D-FB18691
| 1g | Discontinued | ||
| 2g | Discontinued | ||
| 5g | Discontinued | ||
| 10g | Discontinued | ||
| 500mg | Discontinued |
Product Information
- 4,4'-(Hydroxymethylene)bisbenzonitrileBis(p-cyanophenyl)methanolCGP 44645
- 4,4'-(Hydroxymethanediyl)Dibenzonitrile
- 4,4'-Dicyanobenzhydrol
- 4,4′-(Hydroxymethylene)bis[benzonitrile]
- 4,4′-Methanolbisbenzonitrile
- 4-[(4-Cyanophenyl)(hydroxy)methyl]benzonitrile
- 4-[A-(4-Cyanophenyl)-Hydroxymethyl]-Benzonitrile
- 4-[a-(4-Cyanophenyl)-hydroxymethyl]-benzonitrile(ForLetrozole)
- 4-[alpha-(4-Cyanophenyl)hydroxymethyl]benzonitrile
- 4-[α-(4-Cyanophenyl)-hydroxymethyl]-benzonitrile ( For Letrozole )
- See more synonyms
- Benzonitrile, 4,4′-(hydroxymethylene)bis-
- Bis(p-cyanophenyl)methanol
- Cgp 44645
Bis(4-cyanophenyl)methanol (BPM) is a toxic substance that is metabolized by the liver to 4-cyanophenol (4CP). BPM is used in clinical pharmacology as a marker for hepatic uptake and metabolism. BPM has been shown to induce cancer in animal studies, but it has not been shown to have any effect on human tissues. The effect of BPM on cancer development may be due to its ability to inhibit estrogen synthesis.
BPM also inhibits the enzyme aromatase, which converts androstenedione into estrone, which is then converted into estradiol.
Bis(4-cyanophenyl)methanol has also been shown to reduce the effects of letrozole, a drug commonly used in the treatment of breast cancer.
The concentration of BPM in plasma after oral ingestion varies with gender; women have higher concentrations than men at all time points after ingestion.
